Evidence map›Paper›PMID 32529780›Full record

ArticleCancer medicine2020

Effects of adaptive immune cell therapy on the immune cell profile in patients with advanced gastric cancer.

Miyabi Miura, Eishiro Mizukoshi, Tomomi Hashiba, Masaaki Kitahara, Tomoharu Miyashita, Takafumi Mochizuki, Shigenori Goto, Takashi Kamigaki, Rishu Takimoto, Taro Yamashita and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Miyabi MiuraDepartment of Gastroenterology, Graduate School of Medicine, Kanazawa University, Kanazawa City, Japan.ORCID 0000-0002-9922-0155
Eishiro MizukoshiDepartment of Gastroenterology, Graduate School of Medicine, Kanazawa University, Kanazawa City, Japan.
Tomomi HashibaKanazawa Advanced Medical Center, Kanazawa City, Japan.
Masaaki KitaharaKanazawa Advanced Medical Center, Kanazawa City, Japan.ORCID 0000-0003-3053-4356
Tomoharu MiyashitaKanazawa Advanced Medical Center, Kanazawa City, Japan.ORCID 0000-0002-3771-0773
Takafumi MochizukiKanazawa Advanced Medical Center, Kanazawa City, Japan.
Shigenori GotoSeta Clinic Group, Department of Next-Generation Cell and Immune Therapy, Juntendo University School of Medicine, Tokyo, Japan.
Takashi KamigakiSeta Clinic Group, Department of Next-Generation Cell and Immune Therapy, Juntendo University School of Medicine, Tokyo, Japan.
Rishu TakimotoSeta Clinic Group, Department of Next-Generation Cell and Immune Therapy, Juntendo University School of Medicine, Tokyo, Japan.
Taro YamashitaDepartment of Gastroenterology, Graduate School of Medicine, Kanazawa University, Kanazawa City, Japan.
Yoshio SakaiDepartment of Gastroenterology, Graduate School of Medicine, Kanazawa University, Kanazawa City, Japan.
Tatsuya YamashitaDepartment of Gastroenterology, Graduate School of Medicine, Kanazawa University, Kanazawa City, Japan.
Masao HondaDepartment of Gastroenterology, Graduate School of Medicine, Kanazawa University, Kanazawa City, Japan.
Shuichi KanekoDepartment of Gastroenterology, Graduate School of Medicine, Kanazawa University, Kanazawa City, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmunotherapy for cancer patients has been the subject of attention in recent years. In this study, we investigated whether αβT-cell therapy causes changes in the host's immune cell profile, and if so, the effect of these changes on prognosis.

methodsPeripheral blood mononuclear cells (PBMCs) from 30 gastric cancer patients who had completed one course of αβT-cell therapy were analyzed. The peripheral blood immune cell profile was established using PBMCs by counting the frequency of CD4+ helper T cells, CD8+ killer T cells, regulatory T cells (Tregs), and myeloid-derived suppressor cells and measuring the expression of their surface markers. The changes after treatment and their association with response to treatment were investigated.

resultsImmune cell profiles changed greatly after treatment. The frequency of CD4+ helper T cells decreased, but that of CD8+ killer T cells increased. The frequency of programmed cell death 1 (PD-1)+ effector Tregs increased significantly, but only in the non-progressive disease (non-PD) group, in which it was significantly higher compared with the PD group. Patients in whom the frequency of PD-1+ effector Tregs increased had a significantly better prognosis than those in whom it decreased.

conclusionOur results suggested that αβT-cell therapy changes the host's immune cell profile, and an increase in PD-1+ effector Tregs may help improve prognosis.

Indexed as

FemaleHumansImmunotherapyMaleMiddle AgedStomach Neoplasmsgastric cancerimmune cell profileimmunotherapyPD-1αβT-cell therapy

Identifiers

PMID32529780
PMCPMC7367616

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.